Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Malaria
NITAG documentation
SAGE documentation
2024
2021
Clear all
Type of publications
Guidelines
(1)
NITAG documentation
(166)
SAGE documentation
(5)
Scientific publications
(1)
Systematic reviews (SYSVAC)
(261)
Topics
Agenda & Minutes
(2)
Background paper
(27)
Evidence to recommendation table
(1)
Position paper
(3)
Recommendation
(137)
SAGE background document
(1)
Available to download in languages
English (EN)
(119)
French (FR)
(36)
Spanish (ES)
(12)
German (DE)
(7)
Swedish (SV)
(1)
Regions
Africa
(16)
Americas
(62)
Europe
(75)
South-East Asia
(2)
Western Pacific
(11)
Countries
Diseases
COVID-19
(170)
Malaria
(1)
Dengue
(4)
Ebola
(1)
Hepatitis B
(1)
Herpes zoster
(2)
Influenza
(6)
Measles
(1)
Meningococcal disease
(1)
Mpox // Monkeypox
(1)
Pneumococcal disease
(5)
Poliomyelitis
(2)
Rotavirus
(3)
RSV (Respiratory syncytial virus)
(3)
Varicella
(1)
Vaccine topics
Target population
Adults
(3)
Children
(3)
Older adults
(2)
Pregnant women
(4)
Risk group
(2)
Publication date
2024
(3)
2021
(168)
2023
(27)
2022
(109)
2020
(89)
2019
(10)
2018
(15)
2017
(26)
2016
(17)
2015
(18)
2014
(17)
2013
(8)
2012
(1)
2011
(6)
2010
(4)
2009
(4)
2008
(5)
2007
(4)
171 results found
2024
∙
SAGE
Malaria vaccine: WHO position paper – May 2024
2024
∙
JCVI
JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future COVID-19 vaccination
2024
∙
NACI
Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19
2021
∙
Comité Nacional de Inmunización (CNI)
Vaccination, prevention against COVID in children under 12 years old in Bolivia
2021
∙
Comité Nacional de Inmunización (CNI)
Vaccination of pregnant women
2021
∙
SAGE
Background document on the Bharat Biotech BBV152 COVAXIN® (COVID-19) vaccine
2021
∙
SAGE
Annexes to the interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19
2021
∙
ACIP
Adverse events among children ages 5–11 years after COVID-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS)
2021
∙
ATAGI
ATAGI statement on AstraZeneca vaccine in response to new vaccine safety concerns - 8 April, 2021
2021
∙
ACIP
COVID-19 Vaccine Safety Technical (VaST) Work Group
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register